De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial-Reference-Cited by-同舟云学术

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

Published:2017-07 Issue:7 Volume:4 Page:e310-e316
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Clark Richard E,Polydoros Fotios,Apperley Jane F,Milojkovic Dragana,Pocock Christopher,Smith Graeme,Byrne Jenny L,de Lavallade Hugues,O'Brien Stephen G,Coffey Tony,Foroni Letizia,Copland Mhairi

Publisher

Elsevier BV

Subject

Hematology

Reference20 articles.

1. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population;Bower;J Clin Oncol,2016

2. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia;Steegmann;Leukemia,2016

3. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts;Blood,2013

4. Moving treatment-free remission into mainstream clinical practice in CML;Hughes;Blood,2016

5. The concept of treatment-free remission in chronic myeloid leukemia;Saußele;Leukemia,2016

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The frequency of cardiovascular events caused by second-generation tyrosine kinase inhibitors may depend on the treatment intensity in patients with chronic myeloid leukemia;2024-08-18

2. Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety;Meditsinskiy sovet = Medical Council;2024-07-25

3. Chronic myeloid leukaemia: Biology and therapy;Blood Reviews;2024-05

4. A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05

5. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan;Clinical Lymphoma Myeloma and Leukemia;2024-05